The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes

Semaglutide use is associated with a reduced risk of pseudarthrosis following posterior lumbar fusion in patients with T2DM. Further studies are warranted to elucidate the mechanisms underlying this potential benefit and to assess its implications in broader patient populations.